Your Health, We Care

Home >Drug List>Zongertinib>Indications of Zongertinib

Zongertinib(LuciZonger)

Release date: 2026-10-21 13:55:59     Recommended: 3

for adult patients with unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC) harboring activating mutations in the HER2 (ERBB2) tyrosine kinase domain.